Trial Profile
Study of early-period relative dose intensity in first-line sunitinib therapy with a 2-weeks-on and 1-week-off regimen for metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 New trial record